Trials / Recruiting
RecruitingNCT07110038
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
DEPECA-1 - DEfeating PEnile Cancer 1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The DEPECA-1 trial is the first systematic Phase II trial to evaluate response and survival to a combination of antibody-drug conjugate enfortumab vedotin plus the PD-L1 inhibitor avelumab in patients with locally advanced and metastatic penile squamous cell carcinoma (PeCa) in the 1st line setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avelumab | Avelumab, 1,200 mg IV |
| DRUG | enfortumab vedotin | Enfortumab vedotin, 1.25 mg/kg IV |
Timeline
- Start date
- 2025-12-16
- Primary completion
- 2029-05-01
- Completion
- 2030-11-01
- First posted
- 2025-08-07
- Last updated
- 2026-04-16
Locations
7 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT07110038. Inclusion in this directory is not an endorsement.